Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set

Journal of Affective Disorders

Volumn 191, Issue , 2016, Pages 209-215

  Fond, G ^a,b,c,e,m   Godin, O ^a,d   Brunel, L ^a,b,c,e,m   Aouizerate, B ^a,e,m,o   Berna, F ^a,b,c,f,m   Bulzacka, E ^a,b,c,e,m   Capdevielle, D ^a,f,g,m   Chereau, I ^a,h   Dorey, J M ^a,g,i,m   Dubertret, C ^a,j,m   Dubreucq, J ^a,i,k,m   Faget, C ^a,k,l,m   Gabayet, F ^a,i,k,m   Le Strat, Y ^a,j,m   Micoulaud Franchi, J M ⁿ   Misdrahi, D ^a,e,h,m,p   Rey, R ^a,g,i,m   Richieri, R ^a,l   Passerieux, C ^a,l,m   Schandrin, A ^a,f,g,m   Schurhoff F ^a,b,c,e,m   Tronche, A M ^a,d,h,m   Urbach, M ^a,l,m   Vidalhet, P ^f   Llorca, P M ^a,d,h,m   Leboyer, M ^a,b,c,e,m   Blanc, O ^d,m   Chereau Boudet, I ^d,m   Chesnoy Servanin, G ^g,m   Danion, J M ^b,c,m   D'Amato, T ^g,m   Deloge, A ^h,m   Delorme, C ^i,m   Denizot, H ^d,m   De Pradier, M ^j,m   Fluttaz, C ^i,m   Fonteneau, S ^l,m   Giraud Baro, E ^i,m   Hardy Bayle, M C ^l,m   Lacelle, D ^d,m   Lancon C ^k,m   Laouamri, H ^m   Le Gloahec, T ^e,m   Metairie, E ^k,m   Offerlin Meyer, I ^b,c,m   Peri, P ^k,m   Pires, S ^d,m   Portalier, C ^j,m   Roman, C ^i,m   Sebilleau, M ^l,m   Tessier, A ^h,m   Vaillant, F ^k,m   Vehier, A ^g,m   Vidailhet, P ^b,c,m   Vila E ^h,m   Yazbek, H ^f,m   Zinetti Bertschy, A ^b,c,m   more..

^a FONDATION FONDAMENTAL   (France)

^b INSERM U955   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁱ UNIVERSITÉ LYON 1   (France)

^j INSERM   (France)

^k C3R Grenoble   (France)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^m LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

ⁿ HÔPITAL PELLEGRIN   (France)

^o INSTITUT FRANÇOIS MAGENDIE   (France)

^p CNRS   (France)

more..

Author keywords

Abdominal obesity; Antidepressant; C reactive protein (CRP); Depression; Metabolic syndrome; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; GLUCOSE; BIOLOGICAL MARKER;

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY MASS; CALGARY DEPRESSION SCALE; CANNABIS USE; COMMUNITY LIVING; DEMOGRAPHY; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEPHELOMETRY; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SYMPTOMATOLOGY; TOBACCO USE; WAIST CIRCUMFERENCE; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE;

ADULT; ANTIDEPRESSIVE AGENTS; BIOMARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; COHORT STUDIES; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; INFLAMMATION; MALE; METABOLIC SYNDROME X; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; WAIST CIRCUMFERENCE;

EID: 84949426925     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2015.11.017     Document Type: Article

References (55)

1. D. Addington, J. Addington, and E. Maticka-Tyndale Assessing depression in schizophrenia: the Calgary Depression Scale Br. J. Psychiatry. 22 1993 39 44
2. K.G.M.M. Alberti, P. Zimmet, and J. Shaw Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation Diabet. Med. 23 2006 469 480 10.1111/j.1464-5491.2006.01858.x
3. A. Arakelyan, R. Zakharyan, A. Khoyetsyan, D. Poghosyan, R. Aroutiounian, F. Mrazek, M. Petrek, and A. Boyajyan Functional characterization of the complement receptor type 1 and its circulating ligands in patients with schizophrenia BMC Clin. Pathol. 11 2011 10 10.1186/1472-6890-11-10
4. F. Bartoli, C. Crocamo, M. Clerici, and G. Carrà Second-generation antipsychotics and adiponectin levels in schizophrenia: a comparative meta-analysis Eur. Neuropsychopharmacol. 25 2015 1767 1774 10.1016/j.euroneuro.2015.06.011
5. R. Belzeaux, L. Boyer, E.C. Ibrahim, and F. Féron Mood disorders are associated with a more severe hypovitaminosis D than schizophrenia Psychiatry Res. 229 2015 613 616 10.1016/j.psychres.2015.04.039
6. W. Beumer, R.C. Drexhage, H. De Wit, M.A. Versnel, H.A. Drexhage, and D. Cohen Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome Psychoneuroendocrinology 37 2012 1901 1911 10.1016/j.psyneuen.2012.04.001
7. N. Chavda, N.D. Kantharia, and null Jaykaran Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression J. Pharmacol. Pharmacother. 2 2011 11 16 10.4103/0976-500X.77091
8. P.Y. Collins, V. Patel, S.S. Joestl, D. March, T.R. Insel, A.S. Daar, I.A. Bordin, E.J. Costello, M. Durkin, C. Fairburn, R.I. Glass, W. Hall, Y. Huang, S.E. Hyman, K. Jamison, S. Kaaya, S. Kapur, A. Kleinman, A. Ogunniyi, A. Otero-Ojeda, M.-M. Poo, V. Ravindranath, B.J. Sahakian, S. Saxena, P.A. Singer, D.J. Stein, W. Anderson, M.A. Dhansay, W. Ewart, A. Phillips, S. Shurin, and M. Walport Grand challenges in global mental health Nature 475 2011 27 30 10.1038/475027a
9. A.A. Dargél, O. Godin, F. Kapczinski, D.J. Kupfer, and M. Leboyer C-reactive protein alterations in bipolar disorder: a meta-analysis J. Clin. Psychiatry 76 2015 142 150 10.4088/JCP.14r09007
10. J.-P. Després, and I. Lemieux Abdominal obesity and metabolic syndrome Nature 444 2006 881 887 10.1038/nature05488
11. F. Dickerson, C. Stallings, A. Origoni, J. Boronow, and R. Yolken C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia Schizophr. Res. 93 2007 261 265 10.1016/j.schres.2007.03.022
12. F. Dickerson, C. Stallings, A. Origoni, C. Vaughan, S. Khushalani, S. Yang, and R. Yolken C-reactive protein is elevated in schizophrenia Schizophr. Res. 143 2013 198 202 10.1016/j.schres.2012.10.041
13. R.C. Drexhage, T.A. Hoogenboezem, D. Cohen, M.A. Versnel, W.A. Nolen, N.J.M. Beveren, and H.A. van, Drexhage An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces Int. J. Neuropsychopharmacol. 14 2011 746 755 10.1017/S1461145710001653
14. H.E. Duivis, N. Vogelzangs, N. Kupper, P. de Jonge, and B.W.J.H. Penninx Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: findings from the Netherlands Study of Depression and Anxiety (NESDA) Psychoneuroendocrinology 38 2013 1573 1585 10.1016/j.psyneuen.2013.01.002
15. Emerging Risk Factors Collaboration, N. Sarwar, P. Gao, S.R.K. Seshasai, R. Gobin, S. Kaptoge, E. Di Angelantonio, E. Ingelsson, D.A. Lawlor, E. Selvin, M. Stampfer, C.D.A. Stehouwer, S. Lewington, L. Pennells, A. Thompson, N. Sattar, I.R. White, K.K. Ray, and J. Danesh Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet Lond. Engl. 375 2010 2215 2222 10.1016/S0140-6736(10)60484-9
16. X. Fan, C. Pristach, E.Y. Liu, O. Freudenreich, D.C. Henderson, and D.C. Goff Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia Psychiatry Res. 149 2007 267 271 10.1016/j.psychres.2006.07.011
17. M.H. Fawzi, M.M. Fawzi, M.M. Fawzi, and N.S. Said C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia Psychiatry Res. 190 2011 91 97 10.1016/j.psychres.2011.05.010
18. G. Fond, L. Boyer, A. Gaman, H. Laouamri, D. Attiba, J.-R. Richard, M. Delavest, J. Houenou, P. Le Corvoisier, D. Charron, R. Krishnamoorthy, J. Oliveira, R. Tamouza, R. Yolken, F. Dickerson, M. Leboyer, and N. Hamdani Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: a cross-sectional study J. Psychiatr. Res. 63 2015 58 64 10.1016/j.jpsychires.2015.02.011
19. G. Fond, M.-A. d' Albis, S. Jamain, R. Tamouza, C. Arango, W.W. Fleischhacker, B. Glenthøj, M. Leweke, S. Lewis, P. McGuire, A. Meyer-Lindenberg, I.E. Sommer, I. Winter-van Rossum, S. Kapur, R.S. Kahn, D. Rujescu, and M. Leboyer The promise of biological markers for treatment response in first-episode psychosis: a systematic review Schizophr. Bull. 41 2015 559 573 10.1093/schbul/sbv002
20. G. Fond, S. Guillaume, I. Jaussent, S. Beziat, A. Macgregor, P. Bernard, P. Courtet, D. Bailly, and X. Quantin Prevalence and smoking behavior characteristics of nonselected smokers with childhood and/or adult self-reported ADHD symptoms in a smoking-cessation program: a cross-sectional study J. Atten. Disord. 19 2013 293 300 10.1177/1087054713497396
21. G. Fond, N. Hamdani, F. Kapczinski, W. Boukouaci, N. Drancourt, A. Dargel, J. Oliveira, E. Le Guen, E. Marlinge, R. Tamouza, and M. Leboyer Effectiveness and tolerance of anti-inflammatory drugs′ add-on therapy in major mental disorders: a systematic qualitative review Acta Psychiatr. Scand. 129 2014 163 179 10.1111/acps.12211
22. H. Häfner, K. Maurer, G. Trendler, W. an der Heiden, M. Schmidt, and R. Könnecke Schizophrenia and depression: challenging the paradigm of two separate diseases - a controlled study of schizophrenia, depression and healthy controls Schizophr. Res. 77 2005 11 24 10.1016/j.schres.2005.01.004
23. M.B. Howren, D.M. Lamkin, and J. Suls Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis Psychosom. Med. 71 2009 171 186 10.1097/PSY.0b013e3181907c1b
24. N. Ishikawa, Y. Kobayashi, Y. Fujii, and M. Kobayashi Increased interleukin-6 and high-sensitivity C-reactive protein levels in pediatric epilepsy patients with frequent, refractory generalized motor seizures Seizure 25 2015 136 140 10.1016/j.seizure.2014.10.007
25. S.R. Kay, A. Fiszbein, and L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 13 1987 261 276
26. B.A. Kravitz, M.M. Corrada, and C.H. Kawas Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old Alzheimers Dement. 5 2009 318 323
27. J. Kucerova, Z. Babinska, K. Horska, and H. Kotolova The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression Biomed. Pap. Med. Fac. Univ. Palacký Olomouc Czech. Repub. 159 2015 208 214 10.5507/bp.2014.060
28. H.-K. Kuo, C.-J. Yen, C.-H. Chang, C.-K. Kuo, J.-H. Chen, and F. Sorond Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis Lancet Neurol. 4 2005 371 380
29. D. Laurin, J.D. Curb, K.H. Masaki, L.R. White, and L.J. Launer Midlife C-reactive protein and risk of cognitive decline: a 31-year follow-up Neurobiol. Aging 30 2009 1724 1727
30. I. Lemieux, A. Pascot, D. Prud'homme, N. Alméras, P. Bogaty, A. Nadeau, J. Bergeron, and J.P. Després Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity Arterioscler. Thromb. Vasc. Biol. 21 2001 961 967
31. A.L. Lopresti, G.L. Maker, S.D. Hood, and P.D. Drummond A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers Prog. Neuropsychopharmacol. Biol. Psychiatry 48 2014 102 111 10.1016/j.pnpbp.2013.09.017
32. A. Mancinella, M. Mancinella, G. Carpinteri, A. Bellomo, C. Fossati, V. Gianturco, A. Iori, E. Ettorre, G. Troisi, and V. Marigliano Is there a relationship between high C-reactive protein (CRP) levels and dementia? Arch Gerontol. Geriatr. 49 2009 185 194
33. B.J. Miller, N. Culpepper, and M.H. Rapaport C-Reactive Protein Levels in Schizophrenia Clin. Schizophr. Relat. Psychoses 7 2014 223 230 10.3371/CSRP.MICU.020813
34. B.J. Miller, N. Culpepper, M.H. Rapaport, and P. Buckley Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies Prog. Neuropsychopharmacol. Biol. Psychiatry 42 2013 92 100 10.1016/j.pnpbp.2012.03.010
35. A.J. Mitchell, D. Vancampfort, K. Sweers, R. Winkel, W. van, Yu, and M.D. Hert Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - a systematic review and meta-analysis Schizophr. Bull. 39 2013 306 318 10.1093/schbul/sbr148
36. N. Müller Immunology of major depression Neuroimmunomodulation 21 2014 123 130 10.1159/000356540
37. J. Ni, S. Hu, J. Zhang, W. Tang, W. Lu, and C. Zhang A preliminary genetic analysis of complement 3 gene and schizophrenia Plos One 10 2015 e0136372 10.1371/journal.pone.0136372
38. A. Pan, N. Keum, O.I. Okereke, Q. Sun, M. Kivimaki, R.R. Rubin, and F.B. Hu Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies Diabetes Care 35 2012 1171 1180 10.2337/dc11-2055
39. S. Potvin, E. Stip, A.A. Sepehry, A. Gendron, R. Bah, and E. Kouassi Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review Biol. Psychiatry 63 2008 801 808 10.1016/j.biopsych.2007.09.024
40. J. Schaefer, E. Giangrande, D.R. Weinberger, and D. Dickinson The global cognitive impairment in schizophrenia: consistent over decades and around the world Schizophr. Res. 150 2013 42 50 10.1016/j.schres.2013.07.009
41. F. Schürhoff, G. Fond, F. Berna, E. Bulzacka, J. Vilain, D. Capdevielle, D. Misdrahi, M. Leboyer, P.-M. Llorca, and FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) collaborators A National network of schizophrenia expert centres: an innovative tool to bridge the research-practice gap Eur. Psychiatry 30 2015 728 735 10.1016/j.eurpsy.2015.05.004
42. E.G. Severance, K.L. Gressitt, C.R. Stallings, A.E. Origoni, S. Khushalani, F.M. Leweke, F.B. Dickerson, and R.H. Yolken Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia Schizophr. Res. 148 2013 130 137 10.1016/j.schres.2013.05.018
43. S.G. Siris Depression in schizophrenia: perspective in the era of "Atypical" Antipsychotic Agents Am. J. Psychiatry 157 2000 1379 1389 10.1176/appi.ajp.157.9.1379
44. I.E. Sommer, R. Westrhenen, M.J.H. van, Begemann, L.D. Witte, S. de Leucht, and R.S. Kahn Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update Schizophr. Bull. 40 2013 181 191 10.1093/schbul/sbt139
45. R. Strawbridge, D. Arnone, A. Papadopoulos, A. Herane Vives, and A.J. Cleare Inflammation and clinical response to treatment in depression: a meta-analysis Eur. Neuropsychopharmacol. 25 2015 1532 1543
46. R. Uher, K.E. Tansey, T. Dew, W. Maier, O. Mors, J. Hauser, M.Z. Dernovsek, N. Henigsberg, D. Souery, A. Farmer, and P. McGuffin An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline Am. J. Psychiatry 171 2014 1278 1286 10.1176/appi.ajp.2014.14010094
47. V. Valkanova, K.P. Ebmeier, and C.L. Allan CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies J. Affect. Disord. 150 2013 736 744 10.1016/j.jad.2013.06.004
48. N. Vogelzangs, H.E. Duivis, A.T.F. Beekman, C. Kluft, J. Neuteboom, W. Hoogendijk, J.H. Smit, P. de Jonge, and B.W.J.H. Penninx Association of depressive disorders, depression characteristics and antidepressant medication with inflammation Transl. Psychiatry 2 2012 e79 10.1038/tp.2012.8
49. B. Vuksan-Cusa, M. Sagud, M. Jakovljevic, A.M. Peles, N. Jaksic, S. Mihaljevic, M. Zivkovic, S.K. Mikulic, and S. Jevtovic Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia Nord. J. Psychiatry 67 2013 320 325 10.3109/08039488.2012.745601
50. S.P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R.L. Leibel, and A.W. Ferrante Obesity is associated with macrophage accumulation in adipose tissue J. Clin. Invest. 112 2003 1796 1808 10.1172/JCI19246
51. H.U. Wittchen, F. Jacobi, J. Rehm, A. Gustavsson, M. Svensson, B. Jönsson, J. Olesen, C. Allgulander, J. Alonso, C. Faravelli, L. Fratiglioni, P. Jennum, R. Lieb, A. Maercker, J. van Os, M. Preisig, L. Salvador-Carulla, R. Simon, and H.-C. Steinhausen The size and burden of mental disorders and other disorders of the brain in Europe 2010 Eur. Neuropsychopharmacol. 21 2011 655 679 10.1016/j.euroneuro.2011.07.018
52. M.K. Wium-Andersen, D.D. Orsted, and B.G. Nordestgaard Elevated C-reactive protein, depression, somatic diseases, and all-cause mortality: a mendelian randomization study Biol. Psychiatry 76 2014 249 257 10.1016/j.biopsych.2013.10.009
53. J.S. Yudkin, C.D. Stehouwer, J.J. Emeis, and S.W. Coppack C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 19 1999 972 978
54. A. Zalli, O. Jovanova, W.J.G. Hoogendijk, H. Tiemeier, and L.A. Carvalho Low-grade inflammation predicts persistence of depressive symptoms Psychopharmacology (Berl.) 2015 10.1007/s00213-015-3919-9
55. D.-M. Zhu, Y. Liu, A.-G. Zhang, Z.-X. Chu, Q. Wu, H. Li, J.-F. Ge, Y. Dong, and P. Zhu High levels of vitamin D in relation to reduced risk of schizophrenia with elevated C-reactive protein Psychiatry Res. 228 3 2014 565 570 10.1016/j.psychres.2015.05.051